

Alternatives To Animal Experimentation



June 6-7, 2023 • Biocitech Paris-Romainville

GOLD SPONSOR



SILVER SPONSORS



BRONZE SPONSORS



Day One: Tuesday June 6th

9h30

Welcome Coffee and registration (Auditorium Pasteur, Biocitech)

10h00-12h00

Pre-conference technology workshops and demos (Conference foyer)

Important: Access to workshops / demos is exclusively limited to participants duly registered to the plenary conference and should be booked separately

- **Workshop 1:** **MatTek** tissue models
- **Workshop 2:** **NETRI** Organs-on-chip architectures and High-throughput microfluidics platform NeoBento
- **Workshop 3:** **ALTERTOX "TATAbbox"** edutainment game meant to open a conversation about NAMs and validation process in a fun and convivial environment.

14h00-15h00 **Plenary Conference starts - Welcome and Keynote**

14h00 **Welcome by Conference organizers**

Sylvio BENGIO, **Adebiotech** / **Christophe DINI**, **Oroxcell**

14h15 **Keynote lectures**

Amy CLIPPINGER, **PETA Science Consortium International e.V. (USA)**

15h00-18h00 **Session 1 - INNOVATIONS: New Alternative Methods (NAMs) and new approaches to reduce animal testing**

Session chair: Nico FORRAZ, CTIBiotech

15h00 **Patricia MARTIN**, **VIBIOSPHEN**

Apical out lung organoids as a relevant tool to study respiratory diseases

15h20 **Thibault HONEGGER**, **NETRI**

Brain-on-chip devices/ integration of different technologies into the same chip

15h40 **Sinan KARABOGA** / **Stéphane GÉGOUT**, **HARMONIC PHARMA**

QSAR assisted Predictive toxicology and animal experimentation replacement

16h00 **Yuri DANCİK**, **CERTARA (USA / UK)**

In vitro-in vivo extrapolation of dermal absorption of topically applied drug products using physiologically based pharmacokinetic (PBPK) modeling.

16h20 *Coffee break*

17h00 **Nicolas VIOLLE**, **ETAP-LAB**

Reducing animal use in efficacy studies of complex neurological diseases: good and bad news

17h20 **Gregory LEMKINE**, **WATCHFROG LABORATORIES**

New Alternative Methods (NAMs) for endocrine disruptors testing lessons learnt from applying OECD guidelines

17h40 **Jérôme CARON**, **CYPRIO**

Encapsulated spheroids applications

18h00 *Short presentations*

18h00 **Leslie COUEDELO**, **ITERG**

Nutrition – alternative to in vivo model

18h10 **Sébastien RENOUF**, **PathoQuest**

RNA Next-Generation Sequencing transcriptomics analysis: an alternative validated method to replace animal in vivo tests for assessing the viral safety of cell based Biologics

18h20-19h30

FLASH CORPORATE PRESENTATIONS

Altertox, Valentin SALAMONE

CTIBiotech, Nico FORRAZ

Episkin, Christelle VIDEAU

Epithelix, Samuel CONSTANT

Fluigent,

Harmonic Pharma, Aurélien STAB

MatTek, Miroslav KANĎÁR

NETRI, Thibault HONEGGER

Oroxcell, Christophe DINI

PerkinElmer, Julian BURSZTYKA

SABEU, Karina CUANALO-CONTRERAS

Vibiosphen, Patricia MARTIN



19h30-20h30
COCKTAIL



Day Two: Wednesday June 7th

9h00

Welcome Coffee (Auditorium Pasteur, Biocitech)

9h30-11h00

Session 2 - Pharmaceutical industry applications

Session chairs: Corinne Guicheney Galapagos / Christophe DINI, Oroxcell

9h30 Valérie CZEPCZOR, SANOFI

in vitro ADME, our Challenges to Support Research Projects, how can we better predict cerebral or tumor penetration and therapeutic protein PK parameters, with the support of 3D cultures, microfluidic systems and “new” in vitro matrices?

9h50 Yunhai CUI, BOEHRINGER INGELHEIM GmbH (Germany)

EpilIntestinal microtissues as a model for Firstpass drug metabolism and transport

10h10 Jan-Lund OTTESEN, Novo Nordisk (Denmark)

A future without laboratory animals – what does it take?

10h30 Samuel CONSTANT, EPITHELIX

Models in infectiology and respiratory diseases: OECD validation, safety and efficacy

10h50 Hugues CONTAMIN, PhD, DVM, CEO Cynbiose and Président AFSSI

Therapeutic innovation versus 3R's : managing the transition

11h00-12h00

Session 3 - Chemical industries, medical devices and Cosmetics

Session chair: Christian PELLEVOISIN, MatTek

11h00 Thomas LÉOPOLD, FRANCE CHIMIE

Review of the evolution of REACH requirements and role of the NAM (new alternative methods)

11h20 Peter CORNELIS, NELSON LABS (Belgium)

The Biocompatrail: a challenging hike towards animal-free testing of Medical Devices

11h40 Colin MC GUCKIN, CTIBiotech

Bioimpedance-connected and vascularized 3D bioprinted human skin chip for high throughput efficacy testing

12h00-13h00

FLASH SCIENTIFICS POSTERS

12h00 Éric ANDRES, Oroxcell

Skin sensitization and photosensitization evaluation through LC-MS/MS, HRMS and 3D reconstructed tissue approaches : An integrative evaluation strategy addressing the mixtures challenge

12h05 Mendy BOUVERET, Epithelix

Novel fully primary human airway epithelium-alveolar macrophages in vitro co-cultures models to study host pathogen interactions

12h10 Karina CUANALO-CONTRERAS, SABEU

Membrane technology for tissue engineering

12h15 Alan DUBOIS, GIS FC3R

Mapping of Replacement in France based on the projects submitted for the second call for projects of the FC3R

12h20 Edith FILAIRE, ICARE Laboratoire

Innovative in vitro 3D skin model for safety assessment: a case report for the skin sensitization

12h25 Laure GEOFFROY, INERIS

Francopa's point of view: where are we with the use of NAMs for regulatory purpose?

- 12h30 **Christina LE TANNO**, **UMR1011 - Récepteurs Nucléaires - Maladies Métaboliques et Cardiovasculaires**
Microfluidic pump systems: a way to replace animal models to study aortic endothelial cells response and viability to high shear stress
- 12h35 **Astrid CAPELLO**, **Galapagos**
Assessing compounds using an animal-free testing strategy
- 12h40 **Nicolas GAUDENZIO**, **Genoskin**
The Hyposkin® platform: a unique framework to decipher the early steps of human immune response to vaccines at the site of injection
- 12h45 **Richard NGUYEN**, **Pierre Fabre Dermo-cosmétique**
PhotoSENSIL-18 assay development: enhancing the safety testing of cosmetic raw materials and finished products to support the in vitro photosensitization assessment ?
- 12h50 **Elodie OLIVIER**, **Laboratoire de Chimie-Toxicologie Analytique et Cellulaire, Faculté de Pharmacie, Université Paris Cité**
Hormonal impact of bisphenols A, F and S in human placental cells
- 12h55 **Benoit CUDENNEC**, **UMRT BioEcoAgro 1158 Univ. Lille**
In vitro and in vivo comparison of the DPP-IV inhibitory activity of dietary proteins from different origins after gastrointestinal digestion

13h00 *Buffet lunch, networking*

14h15-15h15 Session 4 - Nutrition

Session chair: Rozenn RAVALLEC, Transborder INRAe BioEcoAgro Unit, Lille University

- 14h15 **Jonna KOPER**, **LESAFFRE**
Intestinal simulators in the 3R context
- 14h35 **Anthony TREIZEBRE**, **LILLE UNIVERSITY**
Organs-on-Chips: a new technological revolution for Food Safety and health impact
- 14h55 **Noémie DANIEL**, **SYMRISE**
Complementary animal and advanced in vitro models to investigate the role of polyphenols and gut microbiota-host relationship in metabolic diseases

15h15-16h30

GENERAL TRANSDISCIPLINARY ROUND TABLE and CONFERENCE CONCLUSIONS

With speakers and participants to the Conference

Quentin BAILLEUL, [Roquette](#)

Nabil BOSCO, [Lesaffre](#)

Jeffrey BROWN, [PETA Science Consortium International e.V.](#)

Pauline DHORDAIN, [Ingredia](#)

Christophe DINI, [Oroxcell](#)

Nico FORRAZ, [CTIBiotech](#)

Corinne GUICHENEY, [Galapagos](#)

Thomas LÉOPOLD, [FRANCE CHIMIE](#)

Jan-Lund OTTESEN, [Novo Nordisk \(Denmark\)](#)

Christian PELLEVOISIN, [MatTek](#)

Rozenn RAVALLEC, [Transborder INRAe BioEcoAgro Unit, Lille University](#)

*The following topics (list not limitative) will be discussed during the round table
between speakers, chairpersons and the audience:*

- Biggest recent highlights of NAMs acceptance in various industries
- Scientific validation vs Regulatory authorities' acceptance
- Do historically regulatory toxicological endpoints need to be revisited?
- Difference between geographies (Europe, USA, Asia)
- What is the economic impact (cost reduction) of NAMs adoption?
- Bridges and differences between NAMs adoption across various industry sectors
- Specificities in nutrition studies
- What further progress animal based CROs need to face in the next years?
- Impact of Corporate Social Responsibility